AB-CHMINACA: Difference between revisions
CSV import |
CSV import |
||
| Line 1: | Line 1: | ||
{{ | {{DISPLAYTITLE:AB-CHMINACA}} | ||
}} | |||
'''AB-CHMINACA''' is a synthetic cannabinoid that | == Overview == | ||
'''AB-CHMINACA''' is a synthetic cannabinoid that acts as a potent agonist of the [[cannabinoid receptor]]s. It is part of a class of compounds that are often used in the production of [[designer drug]]s, which are intended to mimic the effects of [[tetrahydrocannabinol]] (THC), the active component of [[cannabis]]. | |||
[[File:AB-CHMINACA.svg|thumb|right|Chemical structure of AB-CHMINACA]] | |||
AB-CHMINACA | |||
== | == Chemical Structure == | ||
AB-CHMINACA | AB-CHMINACA is chemically classified as an indazole-based synthetic cannabinoid. Its structure includes an indazole core, which is a bicyclic compound consisting of a benzene ring fused to a pyrazole ring. The compound is further characterized by the presence of an amide group and a cyclohexylmethyl side chain. | ||
== | == Pharmacology == | ||
AB-CHMINACA functions as a full agonist at the [[CB1 receptor]] and [[CB2 receptor]], which are part of the [[endocannabinoid system]]. This system is involved in regulating various physiological processes, including mood, memory, and appetite. The activation of these receptors by AB-CHMINACA can lead to psychoactive effects similar to those produced by THC. | |||
== | == Effects and Risks == | ||
The use of AB-CHMINACA has been associated with a range of effects, both desired and adverse. Users may experience euphoria, relaxation, and altered perception. However, the compound can also cause severe side effects, such as [[tachycardia]], [[hypertension]], [[nausea]], [[vomiting]], and [[anxiety]]. In some cases, the use of AB-CHMINACA has been linked to [[seizure]]s, [[psychosis]], and even [[death]]. | |||
== | == Legal Status == | ||
Due to its potential for abuse and harmful effects, AB-CHMINACA is classified as a controlled substance in many countries. It is often included in legislation aimed at regulating synthetic cannabinoids and other [[new psychoactive substances]]. | |||
==Related pages== | == Synthesis == | ||
The synthesis of AB-CHMINACA involves the reaction of an indazole derivative with a cyclohexylmethylamine, followed by the introduction of an amide group. The process requires careful control of reaction conditions to ensure the desired product is obtained. | |||
== Related Compounds == | |||
AB-CHMINACA is structurally related to other synthetic cannabinoids, such as [[AB-FUBINACA]] and [[ADB-CHMINACA]]. These compounds share similar pharmacological profiles and are often encountered in the context of [[recreational drug]] use. | |||
== Related pages == | |||
* [[Synthetic cannabinoids]] | * [[Synthetic cannabinoids]] | ||
* [[Cannabinoid receptor]] | * [[Cannabinoid receptor]] | ||
* [[Designer drug]] | * [[Designer drug]] | ||
* [[Endocannabinoid system]] | * [[Endocannabinoid system]] | ||
[[Category:Synthetic cannabinoids]] | [[Category:Synthetic cannabinoids]] | ||
[[Category:Designer drugs]] | [[Category:Designer drugs]] | ||
Latest revision as of 03:38, 13 February 2025
Overview[edit]
AB-CHMINACA is a synthetic cannabinoid that acts as a potent agonist of the cannabinoid receptors. It is part of a class of compounds that are often used in the production of designer drugs, which are intended to mimic the effects of tetrahydrocannabinol (THC), the active component of cannabis.
Chemical Structure[edit]
AB-CHMINACA is chemically classified as an indazole-based synthetic cannabinoid. Its structure includes an indazole core, which is a bicyclic compound consisting of a benzene ring fused to a pyrazole ring. The compound is further characterized by the presence of an amide group and a cyclohexylmethyl side chain.
Pharmacology[edit]
AB-CHMINACA functions as a full agonist at the CB1 receptor and CB2 receptor, which are part of the endocannabinoid system. This system is involved in regulating various physiological processes, including mood, memory, and appetite. The activation of these receptors by AB-CHMINACA can lead to psychoactive effects similar to those produced by THC.
Effects and Risks[edit]
The use of AB-CHMINACA has been associated with a range of effects, both desired and adverse. Users may experience euphoria, relaxation, and altered perception. However, the compound can also cause severe side effects, such as tachycardia, hypertension, nausea, vomiting, and anxiety. In some cases, the use of AB-CHMINACA has been linked to seizures, psychosis, and even death.
Legal Status[edit]
Due to its potential for abuse and harmful effects, AB-CHMINACA is classified as a controlled substance in many countries. It is often included in legislation aimed at regulating synthetic cannabinoids and other new psychoactive substances.
Synthesis[edit]
The synthesis of AB-CHMINACA involves the reaction of an indazole derivative with a cyclohexylmethylamine, followed by the introduction of an amide group. The process requires careful control of reaction conditions to ensure the desired product is obtained.
Related Compounds[edit]
AB-CHMINACA is structurally related to other synthetic cannabinoids, such as AB-FUBINACA and ADB-CHMINACA. These compounds share similar pharmacological profiles and are often encountered in the context of recreational drug use.
